Minority investment round brings together tech expertise, AI resources and a comprehensive bank network to validate and accelerate SavvyMoney’s growth        

DUBLIN, Calif., Oct. 27, 2025 — SavvyMoney, an industry leader of financial wellness and growth solutions, today announced a $225 million minority investment co-led by PSG and Canapi Ventures, with continued investment from Spectrum Equity. The investment will accelerate SavvyMoney’s product roadmap and go-to-market investments, enabling the company to better serve its core community of over 1,500 financial institutions.

SavvyMoney has been a trusted partner for banks, credit unions and fintechs seeking to deepen consumer relationships through data-driven innovation. As a fast-growing market leader, SavvyMoney is just beginning to expand its portfolio potential. The company’s integrated platform combines real-time credit score insights, financial wellness tools, personalized offers, and an advanced analytics platform, combined with a seamless lending and deposit experience – helping financial institutions of all sizes drive growth and empower consumers to take confident financial action.

“This is the kind of validation every CEO hopes for,” said JB Orecchia, CEO and President of SavvyMoney. “We believe PSG and Canapi didn’t just see an investment opportunity. They saw a company that’s genuinely transforming how financial institutions connect with their customers. We’ve spent years proving that community banks and credit unions can deliver value-driving financial wellness tools when they have the right partner. This partnership gives us the resources and expertise to build on our proven model and show what’s possible when you put customer financial well-being and the financial institution’s goals at the center of everything you do.”

The investment brings together two firms whose combined expertise position SavvyMoney for its next chapter of growth. PSG, which manages approximately $28 billion in assets under management across more than 160 portfolio companies, specializes in scaling growth-stage B2B software platforms. Through its software expertise and operational support, PSG aims to enhance SavvyMoney’s ability to help financial institutions drive greater customer engagement and long-term value.

“In our view, SavvyMoney is leading the market in embedding credit score insights, financial wellness tools, and lending solutions directly into the digital banking experience,” said Chris Nesbitt, Managing Director at PSG. “We’re excited to partner with the team as they continue to expand their suite of innovative products and seek to harness AI to deliver even greater revenue opportunities to financial institutions and their customers.”

Canapi Ventures  brings something equally valuable but entirely different: deep expertise in financial services innovation. Canapi’s limited partners include over 70 financial institutions, ranging from community banks to some of the nation’s largest. This positioning means Canapi has direct insight into what banks need to stay competitive. The firm invests in companies that help banks thrive in a rapidly evolving landscape, making this partnership both a strategic validation of SavvyMoney’s approach and a natural fit for the company’s growth ambitions.

“SavvyMoney is raising the bar for personalized credit insights in digital banking,” said Tom Davis, General Partner at Canapi. “Purpose-built for financial institutions and with strong validation from our bank ecosystem, SavvyMoney delivers tangible value for its customers. It is exactly the kind of team we are proud to partner with.”

Spectrum Equity , which first invested in SavvyMoney in 2021, returned for this round, demonstrating continued confidence in the company’s leadership team and growth strategy. TransUnion, who first invested in the business in 2016, remains a valued strategic partner and shareholder going forward.

SavvyMoney has nearly doubled its institutional footprint to over 1,500 partners since 2021 while expanding its digital banking capabilities through new product offerings and strategic acquisitions like CreditSnap, which now powers intelligent loan origination, deposit, and account onboarding solutions.

Raymond James acted as the exclusive financial advisor to SavvyMoney in this transaction, and Goodwin Procter LLP served as the company’s legal advisor. William Blair served as the exclusive financial advisor to PSG, and Latham & Watkins LLP served as its legal advisor. For more information, visit www.savvymoney.com.

About SavvyMoney
SavvyMoney is an industry leader in financial wellness and growth solutions, extending its reach to over 1,500 banks, credit unions, and fintechs nationwide. The synergy of real-time credit data and advanced digital personalization and marketing tools defines SavvyMoney’s offerings, seamlessly integrating with more than 40 digital banking platforms. What sets SavvyMoney apart is not just its innovative technology but also its hands-on service, coupled with a resolute commitment to assisting financial institutions in fortifying and enriching their consumer relationships. To learn more about SavvyMoney, visit www.savvymoney.com.

About PSG 
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities, and build strong teams. Having backed more than 160 companies and facilitated over 530 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris, and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.

About Canapi Ventures
Canapi is a B2B software and financial technology venture and growth equity platform investing in early to growth-stage companies offering disruptive alternatives to outdated business models and technologies. Backed by the Canapi Alliance – a network of over 70 of the leading financial institutions across the United States – Canapi’s partners have decades of hands-on experience in financial services. Canapi brings unmatched sector experience and best-in-class knowledge, connections, and credibility to founders. To learn more about Canapi, visit www.canapi.com.

About Spectrum Equity
Spectrum Equity is a leading growth equity firm providing capital and strategic support to innovative companies in the information economy. For over 30 years, the firm has partnered with exceptional entrepreneurs and management teams to build long-term value in market-leading internet-enabled software, data, and information services companies.

With offices in Boston, San Francisco, and London, the firm is investing its tenth fund with $2 billion in limited partner capital. Representative investments include Ancestry, Definitive Healthcare, GoodRx, Lucid Software, Origami Risk, Ethoca, SurveyMonkey and Verafin. For more information, including a complete list of portfolio investments, visit our Portfolio page.

Media Contacts
PANBlast for SavvyMoney
Emylee Eyler
[email protected]

PSG
Jackie Ryan
[email protected]

Canapi Ventures
Keenan McCarthy
[email protected]

SOURCE SavvyMoney

OKLAHOMA CITY, Oct. 27, 2025 — More than 800 people attended the 2025 Connect+Cure Gala on Wednesday night, raising $4.7 million to support research and programs at the University of Oklahoma Health Harold Hamm Diabetes Center.

The majority of the funds will go toward research, and a portion will support diabetes outreach and prevention, as well as sponsor participants of Camp Blue Hawk, a residential summer camp for youth ages 9 to 17 with Type 1 diabetes.

Master of ceremonies for the evening was Robin Marsh, an Emmy Award-winning journalist with KWTV News 9 in Oklahoma City. Eight-time Grammy Award winner and Oklahoma native Carrie Underwood provided the entertainment.

The prestigious Harold Hamm International Prize for Biomedical Research in Diabetes was awarded to Professor Dr. Anette-Gabriele Ziegler, director of the Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health. She is also Chair in Diabetes and Gestational Diabetes at Technische Universität München, School of Medicine.

The Hamm Prize recognizes and encourages lasting advances in research related to Type 1 or Type 2 diabetes. It is awarded to an individual who has either demonstrated lifelong contributions to the field or realized a singular advance, especially one that promotes curative potential. The Hamm Prize laureate is selected by a rotating jury of national and international leaders in the diabetes research community and is awarded every two years. The honor includes a $250,000 award, the largest of its kind in the world. It is named for Harold Hamm, chairman and chief executive officer of Oklahoma-based Continental Resources Inc., who provided an endowment to fund the prize in perpetuity.

“Dr. Anette-Gabriele Ziegler’s groundbreaking research is transforming the future of Type 1 diabetes,” Hamm said. “Dr. Ziegler’s work is turning hope into reality, giving families more time, more answers and more reasons to believe that a cure is within reach. This is exactly why this prize was created – to recognize and accelerate game-changing discoveries that make a real difference in the lives of those battling diabetes. What a tremendous evening it was celebrating her remarkable contributions and the incredible progress we’ve made at the Harold Hamm Diabetes Center toward ending diabetes once and for all.”

Ziegler’s research has been at the forefront of translating important research questions into long-term studies, including more than 20 clinical trials and implementing findings into public health. Among her many achievements, she launched the first birth cohort to study when and how Type 1 diabetes begins. She also created a public screening program to detect early signs of Type 1 diabetes, now a model for similar global efforts. In addition, she conducted research that led to a landmark clinical trial resulting in Food and Drug Administration approval for teplizumab, the first immunotherapy drug shown to delay the onset of Type 1 diabetes in at-risk individuals.

“Dr. Ziegler’s vision and dedication have not only deepened our understanding of Type 1 diabetes but also led to new ways of helping patients by delaying the disease’s onset,” said Jed Friedman, Ph.D., director of Harold Hamm Diabetes Center and a professor in the OU College of Medicine. “Her work shows how science and compassion can come together to make a real difference in people’s lives. We’re honored to celebrate her for her remarkable contributions to diabetes research and her lasting impact on public health.”

Also at the Connect+Cure Gala, the University of Oklahoma honored Hamm with the inaugural Crystal Seed Sower Award, a distinction for donors whose philanthropic support of $25 million or more has profoundly shaped the university and the people it serves.

Hamm’s generosity has transformed the OU Health Harold Hamm Diabetes Center into a national leader in diabetes research. Because of his support, the center has assembled a team of dedicated scientists who have made promising discoveries regarding both Type 1 and Type 2 diabetes. Research income from the National Institutes of Health has soared from $5 million to $33 million, and new research space has been added to accommodate growth in the research enterprise.

“Because of Mr. Hamm’s steadfast commitment to the OU Health Harold Hamm Diabetes Center, we are making extraordinary progress in confronting the diabetes crisis,” said OU President Joseph Harroz Jr. “Few individuals have left such an enduring mark on the health and well-being of our state. His philanthropy reflects not only deep compassion, but also a profound belief in the power of discovery to save lives.”

About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. In Oklahoma City, the OU Health Campus is one of the nation’s few academic health centers with seven health profession colleges located on the same campus. The OU Health Campus serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about the OU Health Campus, visit www.ouhsc.edu.

SOURCE University of Oklahoma

Frontier Growth backs spin-out from PingPod to accelerate the expansion of PodPlay’s vertical SaaS platform modernizing participatory sports clubs.

NEW YORK, Oct. 27, 2025 — PodPlay Technologies, Inc., the fast-growing vertical SaaS platform for participatory sports venues, today announced its spin-off from PingPod Inc and the close of an $8 million Series A led by Frontier Growth. Frontier partner Dave Pandullo will join PodPlay’s board.

PodPlay combines software, hardware, and automation to help sports clubs run more efficiently and deliver premium player experiences. Its full stack platform integrates reservations, memberships, coaching, events, and payments with proprietary technology for video replays, digital scoreboards, and autonomous access. Clubs using PodPlay have reduced labor costs by up to 66% while unlocking new digital revenue streams and social engagement.

Originally developed to power PingPod’s autonomous table-tennis clubs, PodPlay has quickly expanded to meet demand in pickleball – the fastest-growing sport in the U.S. – and is now the preferred premium solution for modern, tech-driven venues. Today, PodPlay’s platform powers many of the country’s most innovative pickleball venues – including Pickleball Kingdom, CityPickle, Performance Pickleball, SPF, and St. Pete Athletic.

“PodPlay was built to make sports venues both more human and more autonomous,” said Max Kogler, Co-Founder and CEO of PodPlay Technologies. “Our platform lets owners focus on community and experience while technology handles the rest. Operating independently and partnering with Frontier gives us the runway to accelerate product innovation and bring PodPlay to thousands of venues worldwide.”

Frontier Growth’s investment aligns with its long-standing thesis in vertical SaaS: backing platforms that combine operational depth with modern, scalable tech. “We partner with domain experts who are transforming their industries with modern vertical SaaS solutions that customers love,” said Dave Pandullo, Partner at Frontier Growth. “Our diligence revealed an exceptional level of customer passion for PodPlay – operators who describe it as transformative for their venues and communities. That customer love underscores a significant opportunity to replace the dated, fragmented tools that exist in the market today with a modern, integrated platform purpose-built for participatory sports. We’re thrilled to partner with a team whose deep domain expertise and technology leadership are redefining the category.”

Ben Borton, Co-Founder of PodPlay, added: “The future of sports venues is connected, digital, and frictionless. Frontier’s track record with vertical SaaS leaders will help us scale faster without losing what makes these communities special.”

PodPlay’s growth reflects a broader shift toward participatory, tech-enabled recreation. The company has tripled revenue year-over-year, served nearly one million users, and formed strategic partnerships across the fastest-growing sports categories. With new capital and independence, PodPlay will expand its engineering, sales, and customer-success teams to support rapid adoption and product expansion.

About PodPlay Technologies

PodPlay Technologies is the software and hardware platform for modern recreational venues. It integrates reservations, events, coaching, analytics, and payments with proprietary technology—digital scoreboards, instant video replays, secure access, and 24/7 remote monitoring. Originally built for PingPod, PodPlay now powers next-generation pickleball, padel, ping pong, pool, tennis, golf, and multisport facilities worldwide. Learn more at www.podplay.app.

About Frontier Growth

Founded in 1999, Frontier Growth is a growth equity investment firm based in Charlotte, North Carolina that specializes in partnering with founders of vertical SaaS companies to help them scale and reach new heights. By leveraging its deep experience helping growth-stage vertical SaaS companies scale to market leadership positions, Frontier provides tailored support and resources to help drive sustainable growth and scalability. Frontier’s ‘people-first’ philosophy to investing is founded upon putting people before numbers – a belief that it’s the people around the table collaborating together that make the difference in driving true innovation and growth. With over 15 years of experience investing in vertical SaaS, Frontier has completed more than 25 vertical SaaS investments since inception. Frontier typically makes initial equity investments of $5–30 million in mission critical vertical SaaS companies with $3–20 million of annual recurring revenue (“ARR”) and +25% annual growth. For more information about Frontier, please visit www.frontiergrowth.com.

Media Contact
[email protected]

Logo – https://mma.prnewswire.com/media/2804041/PodPlay__Logo.jpg

PHOENIX, Oct. 27, 2025 — Xcellerant Ventures and Jetstream Venture Fund today celebrate the announcement of the John Shufeldt School of Medicine and Medical Engineering at Arizona State University (ASU), made possible through a transformational nine-figure gift from Dr. John Shufeldt. The new school, a central part of the ASU Health system, received preliminary accreditation from the Liaison Committee on Medical Education and will welcome its first class in 2026.

Dr. Shufeldt’s gift, one of the largest in ASU’s history, establishes a groundbreaking medical school that unites medicine, engineering, and entrepreneurship. The school will prepare students to earn both an MD and a Master of Science in Medical Engineering, training the next generation of clinician-innovators equipped to transform patient care through technology, leadership, and compassion.

Extending the Mission of Innovation and Access

Building on this legacy of innovation, Jetstream Venture Fund, founded by Dr. Shufeldt under the Xcellerant Ventures umbrella, continues his mission to expand access, this time in venture investing.

“John’s gift to ASU represents the same vision that drives Jetstream,” said Mike Shufeldt, General Partner at Xcellerant Ventures. “He’s creating access, whether it’s access to world-class medical education or access to early-stage investing. Both are about empowering people to participate in the innovations shaping the future.”

Jetstream Venture Fund is one of the first interval funds of its kind, providing early through late stage venture access to investors with a minimum $20,000 investment. Designed for accessibility and flexibility, Jetstream removes almost every barrier associated with traditional VC funds while focusing on historically high-growth sectors including HealthTech, MedTech, and BioTech.

“Through Jetstream, we’re opening the doors to early innovation,” said Dr. John Shufeldt, Portfolio Manager of the Jetstream Venture Fund. “Just as ASU’s new medical school will train physician-engineers to reimagine healthcare, Jetstream allows investors to join in building the next generation of transformative companies.”

A Shared Vision for the Future of Health Innovation

The establishment of the John Shufeldt School of Medicine and Medical Engineering represents a major leap forward for Arizona and for health innovation nationwide. The school will partner closely with HonorHealth and ASU’s ecosystem of colleges, including the Edson College of Nursing and Health Innovation and the College of Health Solutions.

“The connection between ASU Health and Jetstream reflects a unified vision,” said Chris Yoo, PhD, Managing Partner at Xcellerant Ventures. “We’re investing in both the people and the ideas that will reshape how medicine is practiced and delivered.”

As ASU begins to recruit its first class for 2026, Jetstream and Xcellerant Ventures stand ready to back founders emerging from this ecosystem, the next wave of innovators working at the intersection of medicine, engineering, and entrepreneurship.

About Jetstream Venture Fund

Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, that seeks to provide investors access to early-stage, high-growth companies with lower minimums and no carried interest. Jetstream is one of the first funds of its kind, bringing venture-style investing opportunities to a wider professional audience. Back-end administration is provided by Sweater Ventures, a ground-breaking turnkey fund management company. For more information, visit https://www.jvf.vc

Disclosure

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Jetstream Venture Fund (the “Fund”) before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing [email protected] or by visiting the Fund’s website at https://www.jvf.vc. Please read the prospectus carefully before investing.

Media Contact: Dawson Fearnow, MMPR Marketing [email protected]

SOURCE Xcellerant Ventures

$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors

Financing readies Hemab for registration studies following successful advancement of sutacimig through Phase 2 in Glanzmann thrombasthenia and continued progress of HMB-002 in Von Willebrand disease

Positions Hemab to continue expanding the clinical pipeline

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Oct. 27, 2025 — Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of a multifold oversubscribed $157 million Series C financing round. The round was led by Sofinnova Partners with substantial participation from a large long-only global asset management company, and participation from additional new investors including a large global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital. In connection with this financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join the Hemab Board.

Advancing Breakthrough Treatments for Glanzmann Thrombasthenia and Factor VII Deficiency

Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder affecting patients worldwide. The financing follows the successful completion of sutacimig’s Phase 2 study in GT with planned advancement to a registration study in 2026, alongside expanding into a Phase 2 study in Factor VII deficiency.

“As a mother of two boys with GT, I live with a constant fear, knowing from experience that a simple fall or injury can lead to a life-threatening bleed,” said Alexandra Sullivan, patient advocate and mother. “We feel so limited by the lack of effective treatments in the event of an emergency and cannot stress enough how urgently we feel the need for breakthrough treatments. Our greatest hope is to offer our children a treatment that will allow them to live normal lives. Investment in the development of modern therapies for these underserved patients brings hope to our family.”

Revolutionizing Von Willebrand Disease Treatment 

The financing also supports advancing HMB-002 towards a registration study. HMB-002 is Hemab’s antibody-based treatment with Phase 1 proof of mechanism data showing that it directly targets the underlying pathophysiology of Von Willebrand disease (VWD) by increasing both Von Willebrand Factor and Factor VIII levels. This innovative approach is designed to address the root cause of the bleeding disorder.

“For too long, people living with von Willebrand Disease have watched from the sidelines as breakthrough prophylactic therapies transformed hemophilia care,” said Jeanette Cesta, Executive Director, VWD Connect Foundation. “HMB-002 represents hope: in its potential to be the kind of innovative, patient-centered treatment our community has been waiting for. It’s time VWD patients had access to the same caliber of medicine that has already changed lives in hemophilia.”

Patients’ Insights Drive Hemab’s Innovation 

From inception, Hemab’s program development has been shaped by a portfolio of groundbreaking natural history studies including GT360, FVIID360 and VWD360, which have challenged historical assumptions and uncovered the overlooked burden of these diseases. Beyond severe, life-threatening bleeds, people face chronic pain, immobility, anxiety, depression and fatigue – yet only reactive or episodic treatments exist.

Expanding Pipeline and Building the Ultimate Clotting Company 

The additional capital enables Hemab to advance additional novel drug candidates into clinical development, with HMB-003 expected to be announced in H1 2026. This expanded pipeline reinforces Hemab’s commitment to developing comprehensive treatment solutions across the spectrum of high unmet need bleeding disorders.

“The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company,” said Benny Sorensen, MD, PhD, CEOof Hemab. “We carefully listen to people living with clotting diseases and collaborate closely with patients and families affected by these conditions and families to deliver 21st century treatment options. Hemab’s unprecedented deep domain expertise in clotting science, combined with our team’s proven capabilities in advancing programs from early development through approval and commercialization, uniquely positions us to deliver breakthrough therapies. This funding accelerates our mission of transforming lives for people who have waited far too long.”

Investor Perspectives support Growth Plans 

“Hemab’s focus on patients and an innovative approach to treating neglected bleeding disorders, combined with their deep scientific excellence and strong clinical execution, makes it a standout company in the biotech landscape,” said Joe Anderson, PhD, Partner at Sofinnova Partners. “Hemab’s progress across multiple clinical programs gives us confidence in the team’s ability to execute on their ambitious pipeline. We’re excited to support their mission to bring transformative treatments to underserved patient populations with significant medical needs.”

About Glanzmann Thrombasthenia
Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international Glanzmann’s 360 (GT360) natural history study revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week, with 34% of those bleeds requiring medical treatment. These bleeding episodes significantly impact patients’ mental health and quality of life, with 67% reporting low mood, 52% reporting emotional problems, and 46% experiencing social isolation. Additionally, 81% of participants reported missing school or work due to bruising or bleeding. To date, there are no effective prophylactic treatment options for GT.

About Sutacimig (formerly HMB-001)
Sutacimig is a subcutaneously administered bispecific antibody that binds and stabilizes endogenous Factor VIIa with one antibody arm and binds to TLT-1 on activated platelets with the other arm. This mechanism allows for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it facilitates hemostatic plug formation. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration granted Fast Track Designation and Orphan Drug Designation to sutacimig for the treatment of GT while the UK Medicines and Healthcare products Regulatory Agency has awarded it designation under the Innovative Licensing and Access Pathway (ILAP). For more information, please visit clinicaltrials.gov (NCT06211634).

About Von Willebrand Disease 
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying defect in VWF production or function.

About HMB-002 
HMB-002 is a monovalent human antibody being developed as the first-in-class prophylactic treatment for Von Willebrand Disease targeting the underlying root cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852).

About Hemab Therapeutics 
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5^TM, targets building a pipeline of development programs to deliver long-awaited innovation for people with high unmet need diseases like Glanzmann thrombasthenia, Factor VII Deficiency, Von Willebrand Disease, and others. Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Media:
Deerfield
Peg Rusconi
[email protected]

Investors:
Hemab Therapeutics
Mads Behrndt
[email protected]

SOURCE Hemab Therapeutics

– La empresa china de Robovan, Neolix, recauda más de 600 millones de dólares en la Serie D, estableciendo un nuevo récord para la industria de conducción autónoma de China

BEIJING, 27 de octubre de 2025 — Neolix, el mayor proveedor mundial de soluciones de reparto autónomo L4 (RoboVan), ha recaudado más de 600 millones de dólares en su ronda de financiación Serie D. Esta ronda supone la mayor recaudación de fondos privados en el sector de la conducción autónoma en China hasta la fecha y se encuentra entre las mayores inversiones privadas en China este año.

La ronda fue liderada por Stone Venture, con sede en los Emiratos Árabes Unidos, a la que se unieron Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund y una de las plataformas de internet más grandes de China. Otros inversores clave incluyen Legend Capital, Gaorong Ventures, Templewater, SAIC, etc. Los nuevos fondos se utilizarán para impulsar los algoritmos patentados de conducción autónoma de Neolix, acelerar el desarrollo de productos en nuevos casos de uso comercial, mejorar su red de servicios y la experiencia del usuario, e impulsar sus planes de expansión global.

Fundada por Enyuan Yu, Neolix se ha consolidado rápidamente como líder mundial en vehículos autónomos de reparto desde su lanzamiento en 2018. La compañía ha entregado más de 10.000 RoboVans L4, más que cualquier otra empresa a nivel mundial, y ha alcanzado un récord de 2.000 entregas de vehículos en un solo mes. Sus vehículos se encuentran actualmente desplegados en más de 300 ciudades de China, y Qingdao alberga más de 1.200 unidades. Los populares modelos X3 y X6 de Neolix han superado las 4.000 entregas cada uno, lo que demuestra una fuerte demanda del mercado.

En el ámbito tecnológico, Neolix ha introducido importantes innovaciones, como su modelo de IA “Neolix-VA” para una navegación fluida en tráfico complejo, un sistema de conducción sin mapas para una logística urbana flexible y una plataforma de despacho inteligente que optimiza la coordinación de vehículos, carreteras y pedidos. Estos avances han ayudado a la flota de Neolix a superar los 50 millones de kilómetros de conducción autónoma.

Desde que obtuvo la primera licencia de reparto autónomo de China en 2021, Neolix ha crecido exponencialmente, alcanzando actualmente más del 60 % de la cuota de mercado en envíos acumulados y atendiendo a más de 300.000 clientes. Domina el sector del reparto exprés y se está expandiendo a servicios de alimentos frescos, cadena de frío y entrega instantánea. A nivel internacional, Neolix está expandiéndose, tras haber obtenido la primera licencia de RoboVan en los EAU en colaboración con una empresa tecnológica con sede en Abu Dabi, lo que marca su expansión global más allá de China.

Foto – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

PEKING, 25. Oktober 2025 — Neolix, der weltweit größte Anbieter von L4-Lösungen für autonome Lieferungen (RoboVan), hat in seiner Serie-D-Finanzierungsrunde über 600 Millionen US-Dollar aufgebracht. Diese Finanzierungsrunde stellt die bislang größte private Kapitalbeschaffung im Bereich autonomes Fahren in China dar und zählt zu den bedeutendsten privaten Investitionen in China in diesem Jahr.

Die Finanzierungsrunde wurde von Stone Venture mit Sitz in den Vereinigten Arabischen Emiraten angeführt, zusammen mit Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund und einer der größten Internetplattformen Chinas. Weitere wichtige Investoren sind Legend Capital, Gaorong Ventures, Templewater, SAIC usw. Die neuen Finanzmittel werden dazu verwendet, die proprietären Algorithmen für autonomes Fahren von Neolix weiterzuentwickeln, die Produktentwicklung für neue kommerzielle Anwendungsfälle zu beschleunigen, das Servicenetzwerk und die Benutzererfahrung zu verbessern sowie die globalen Expansionspläne voranzutreiben.

Neolix wurde von Herrn Enyuan Yu gegründet und hat sich seit seiner Gründung im Jahr 2018 rasch zu einem weltweit führenden Anbieter von autonomen Lieferfahrzeugen entwickelt. Das Unternehmen hat über 10.000 L4 RoboVans ausgeliefert, mehr als jedes andere Unternehmen weltweit, und in einem einzigen Monat die Rekordzahl von 2.000 Fahrzeugauslieferungen erreicht. Seine Fahrzeuge sind mittlerweile in über 300 Städten in China im Einsatz, wobei Qingdao mehr als 1.200 Einheiten beherbergt. Die beliebten Modelle X3 und X6 von Neolix haben jeweils mehr als 4.000 Auslieferungen erreicht, was die starke Nachfrage auf dem Markt verdeutlicht.

Technologisch hat Neolix bedeutende Innovationen eingeführt, darunter sein KI-Modell „Neolix-VA” für eine reibungslose Navigation im komplexen Verkehr, ein kartenloses Fahrsystem für flexible Stadtlogistik und eine intelligente Dispositionsplattform, die die Koordination von Fahrzeugen, Straßen und Aufträgen optimiert. Dank dieser Fortschritte hat die Flotte von Neolix mehr als 50 Millionen Kilometer im autonomen Fahrbetrieb zurückgelegt.

Seitdem Neolix im Jahr 2021 die erste Lizenz für autonome Lieferungen in China erhalten hat, ist das Unternehmen exponentiell gewachsen und hält nun einen Marktanteil von über 60 % bei den kumulierten Lieferungen und bedient mehr als 300.000 Kunden. Das Unternehmen ist führend im Bereich Expresslieferungen und expandiert derzeit in die Bereiche Frischwaren, Kühlketten und Sofortlieferungen. Auf internationaler Ebene expandiert Neolix und hat in Zusammenarbeit mit einem in Abu Dhabi ansässigen Technologieunternehmen die erste RoboVan-Lizenz der Vereinigten Arabischen Emirate erhalten, was seine globale Expansion über China hinaus markiert.

Foto – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

BEIJING, 25 octobre 2025 — Neolix, le plus grand fournisseur mondial de solutions de livraison autonome de niveau 4 (RoboVan), a levé plus de 600 millions de dollars américains dans le cadre de son financement de série D. Ce tour de table représente la plus importante levée de fonds privée dans le secteur de la conduite autonome en Chine à ce jour, et figure parmi les plus gros investissements privés en Chine cette année.

Le tour de table a été mené par Stone Venture, basée aux Émirats arabes unis, rejointe par Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund et l’une des principales plateformes Internet de Chine. Parmi les autres investisseurs clés figurent Legend Capital, Gaorong Ventures, Templewater et SAIC. Les nouveaux fonds seront utilisés pour faire progresser les algorithmes propriétaires de conduite autonome de Neolix, accélérer le développement de produits pour de nouveaux cas d’utilisation commerciale, améliorer son réseau de services et l’expérience des utilisateurs, et alimenter ses plans d’expansion mondiale.

Fondée par M. Enyuan Yu, Neolix s’est rapidement imposée comme un leader mondial des véhicules de livraison autonomes depuis son lancement en 2018. L’entreprise a livré plus de 10 000 RoboVans de niveau 4, soit plus que toute autre entreprise dans le monde, et a battu le record de 2 000 véhicules livrés en un seul mois. Ses véhicules sont aujourd’hui déployés dans plus de 300 villes en Chine, Qingdao accueillant plus de 1 200 unités. Les modèles populaires X3 et X6 de Neolix ont chacun dépassé les 4 000 livraisons, ce qui témoigne de la forte demande du marché.

Sur le plan technologique, Neolix a introduit des innovations majeures, notamment son modèle d’IA « Neolix-VA » pour une navigation fluide dans un trafic complexe, un système de conduite sans carte pour une logistique urbaine flexible, et une plateforme de répartition intelligente qui optimise la coordination des véhicules, des tournées et des commandes. Ces avancées ont permis à la flotte de Neolix de dépasser les 50 millions de kilomètres en conduite autonome.

Depuis qu’elle a reçu la première licence de livraison autonome de Chine en 2021, Neolix a connu une croissance exponentielle, détenant aujourd’hui plus de 60 % des parts de marché en termes de livraisons cumulées et desservant plus de 300 000 clients. Elle domine le secteur de la livraison express et se développe dans les secteurs des produits frais, de la chaîne du froid et des services de livraison instantanée. À l’échelle internationale, Neolix se développe, ayant obtenu la première licence RoboVan des Émirats arabes unis en partenariat avec une société technologique basée à Abou Dhabi, marquant ainsi son expansion mondiale au-delà de la Chine.

Photo – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

Partnership with Bioversity International USA and Yale University will build the Rumen Digital Twin to model and optimize climate–smart feed and microbiome interventions

GREENFIELD, Ind., Oct. 24, 2025 — In partnership with Bioversity International USA and Yale University, BiomEdit, a pioneering animal health biotechnology company, announced today it has been selected as one of 15 global teams awarded funding of nearly $2 million from the Bezos Earth Fund’s AI for Climate and Nature Grand Challenge. The funding will support development of the Rumen Digital Twin, an artificial intelligence (AI) foundation model designed to identify the most effective strategies for reducing methane emissions in cattle while also optimizing animal productivity and welfare.

Together with its partners, BiomEdit will lead the effort to train a generative AI model on data from more than 20,000 ruminants across 25+ countries, including the Global South. The model will integrate publicly available and newly generated data, producing more than 10,000 microbiome profiles crosslinked with methane emissions, diet, host genetics and animal performance data.

The goal of the project is to replace lengthy and expensive animal trials with AI-powered simulations that can identify the precise conditions and animal traits where specific feed additives or interventions will be most effective. These tailored strategies are expected to reduce methane emissions by up to 75% compared to untargeted approaches, while maintaining or improving animal productivity.

“This project reflects the power of the microbiome and the use of AI to reduce methane and improve productivity in livestock,” said Aaron Schacht, CEO of BiomEdit. “With the generous support of the Bezos Earth Fund and in collaboration with Bioversity and Yale, we aim to develop a better understanding of targeted interventions and share that knowledge to positively affect both climate impact and animal well-being.”

Expected outcomes of the project include an open-access, cloud-based platform where users can generate and explore virtual ruminant populations, simulate interventions and fine-tune strategies for methane mitigation and productivity. The platform and model will be made available to research and non-profit organizations globally at no cost, with licensing pathways for commercial developers.

Launched in 2024, the Bezos Earth Fund’s AI for Climate and Nature Grand Challenge is a $100 million initiative designed to harness AI to address the dual crises of climate change and biodiversity loss. The program connects innovators with resources and mentorship from leading technology partners including AWS, Google.org, NVIDIA Corporation, Microsoft Research, AI2, and Esri.

“These projects show how AI, when developed responsibly and guided by science and local knowledge, can strengthen environmental action and ensure its overall impact on the planet is positive,” said Dr. Amen Ra Mashariki, Director of AI and Data Strategies at the Bezos Earth Fund.

The Rumen Digital Twin builds on BiomEdit’s first methane-reduction initiative: a $4.5 million grant from the Gates Foundation awarded in 2023. That program focuses on microbiome-based feed additives to reduce methane in cattle across Africa and South Asia while improving feed efficiency and food security for small-scale producers. Together, the two initiatives reflect BiomEdit’s growing leadership in developing sustainable, microbiome-based climate solutions for agriculture.

About BiomEdit
BiomEdit is an animal health microbial biotechnology company leveraging the power of the microbiome and synthetic biology to develop next-generation solutions for livestock and pet health. Founded in 2022, BiomEdit is backed by leading investors Anterra Capital, Viking Global, Nutreco, AgriZeroNZ, Elevate, and Betagro Ventures, among others. www.biomedit.com

Media Contact:
Julie Lawless
LawlessComms
[email protected]
+1 615-585-5861

SOURCE BiomEdit